RDEA 594 is an active pharmaceutical ingredient used as a uric acid reabsorption inhibitor. It has been investigated in multicomponent solid forms and cocrystal polymorphs for solubility enhancement.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing RDEA 594?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.
Methyl 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate
research reagent
N-Phenylpropyl Alverine Hydrochloride
pharmaceutical raw material
Vismodegib
pharmaceutical raw material
Des(1-hydroxy-1-methylethyl)-(1-methylethenyl)-olmesartan medoxomil
pharmaceutical raw material
Chloroxylenol
pharmaceutical raw material
Methyl 2-((5-amino-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)acetate
research compound
Methyl 2-(4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio) acetate
pharmaceutical intermediate
The international HS code for RDEA 594 (CAS 878672-00-5) is 2933.99.
2933.99
2933 99 80
Classification per the EU customs inventory ECICS (2026-07 snapshot, HS 2022). National tariff lines and product form can affect the final classification.
2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acid
FGQFOYHRJSUHMR-UHFFFAOYSA-N
C1CC1C2=CC=C(C3=CC=CC=C23)N4C(=NN=C4Br)SCC(=O)O
Sourcing RDEA 594?
Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.